Related Experiment Video
Updated: Mar 8, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Predictive factors for survival in neoadjuvant radiochemotherapy for advanced rectal cancer
A Reig Castillejo1, I Membrive2, P Foro2
1Department of Radiation and Oncology, Hospital de l'Esperança, Parc de Salut Mar, C/Sant Josep de la Muntanya, 12, 08024, Barcelona, Spain. areig@parcdesalutmar.cat.
Introduction:
Neoadjuvant radiochemotherapy followed by radical surgery is the standard approach in advanced rectal carcinoma. Tumor response is determined in histological specimen.
Objective:
To assess predictive factors for survival in 115 patients.
Patients And Method:
115 patients treated with neoadjuvant radiochemotherapy followed by radical surgery with total mesorectal excision, in our hospital from January 2007 to December 2014. All patients received pelvic radiotherapy with concomitant chemotherapy, followed by radical surgery and in some adjuvant chemotherapy.
Results:
In univariate analysis, distance to anal verge, radial margin, perineural invasion, and good grade regression are predictive factors for both, specific and disease free survival; and in multivariant, only radial margin and perineural invasion were predictive factors for survival. We found distance to anal verge (<5 cm) as the only clinical factor to predict a positive margin in the histologic specimen.
Conclusions:
Perineural invasion and positive radial margin are predictive factors for both specific and disease free survival.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
07:13Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
Published on: April 18, 2025
Related Concept Videos
Cancer Survival Analysis
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase